Melanocyte-Specific Immune Response in Melanoma and Vitiligo: Two Faces of the Same Coin?
- 1 June 2003
- journal article
- review article
- Published by Wiley in Pigment Cell Research
- Vol. 16 (3) , 254-260
- https://doi.org/10.1034/j.1600-0749.2003.00038.x
Abstract
The appearance of depigmentation during the course of malignant melanoma has been considered a good prognostic sign. Is it only a side-effect, informative of the immune system's response to the treatment, or does it act as a necessary amplifier of these clinically important anti-tumor responses? The current review will attempt to tackle this question by reviewing the current literature, as well as by posing some novel hypotheses. Understanding the nature of humoral and cellular immune responses directed against normal melanocytes and their malignant counterparts may lead to the design of improved therapeutic strategies relevant to both vitiligo and melanoma.Keywords
This publication has 62 references indexed in Scilit:
- Melanoma incidence trendsDermatologic Clinics, 2002
- Tyrosinase: a comprehensive review of its mechanismPublished by Elsevier ,1999
- The expanding universe of T-cell subsets: Th1, Th2 and morePublished by Elsevier ,1999
- Autoantibodies to tyrosinase‐related protein‐1 detected in the sera of vitiligo patients using a quantitative radiobinding assayBritish Journal of Dermatology, 1998
- THE INTERLEUKIN-12/INTERLEUKIN-12-RECEPTOR SYSTEM: Role in Normal and Pathologic Immune ResponsesAnnual Review of Immunology, 1998
- Profiles of Pulp Infiltrating Lymphocytes at Various Times Throughout Feather Regeneration in Smyth Line Chickens with VitiligoAutoimmunity, 1997
- Tumor immunity as autoimmunity: tumor antigens include normal self proteins which stimulate anergic peripheral T cellsImmunology Today, 1993
- Role of Melanin as a Scavenger of Active Oxygen SpeciesPigment Cell Research, 1993
- Vitiligo in patients with metastatic melanoma: A good prognostic signJournal of the American Academy of Dermatology, 1983